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INTRODUCTION
Hodgkin lymphoma (HL) constitutes 6% of all childhood can-
cers. With the use of effective chemotherapy, radiotherapy, and
autologous stem cell transplant (ASCT) in recurrent cases, the
prognosis has improved dramatically in HL [1]. The increase in
survival rate has placed more emphasis on managing long-term
morbidity and mortality among the survivors.
Secondary malignancy (SM) is one of the main contributors to
long-term morbidity and mortality in survivors of HL. The cumu-
lative incidence of SMs 20 years after completion of therapy has
been reported as 10.6%, which increases to 26.3% at 30 years [2].
Acute leukemia, non-HL and solid tumors including soft tissue
sarcomas (STS) are the three main categories of SM [2,3]. While
the former two categories are seen often within the initial few
years following completion of therapy, the latter predominates a
decade following therapy. Depending on length of follow-up and
primary treatment modality, STS constitute 8–19% of all SM
cases in HL patients [3,4]. Alkylating chemotherapy, radiother-
apy, and postulated inherent defects have been proposed as the
risk factors for SM development in HL, of which radiotherapy is
the major risk factor for STS.
Malignant fibrous histiocytoma (MFH), a form of STS is rare
after HL therapy; very few cases have been reported in the adult
literature [5–8]. Moreover, most of the post-radiation sarcomas
develop more than 10 years following the initial therapy [5–8].
We report a 14 years old autistic male with HL who developed
MFH within 3 years of initial HL treatment and 2 years of ASCT
and discuss the potential role of genomic instability in early onset
SM.
CASE REPORT
A 14 year old autistic male was diagnosed with nodular scle-
rosing, stage IV-B HL. At presentation, he had extensive tumor
burden with bulky intra-thoracic lymphadenopathy, pulmonary
nodules bilaterally and large left pleural effusion, enlarged lymph
nodes within the periportal and peripancreatic region, and lesions
in the anterior cortex of both kidneys. A positron emission tom-
ography (PET) scan demonstrated numerous foci of abnormal
FDG activity corresponding to the findings noted on the contrast
enhanced CT scan. Cytogenetic evaluation of the involved lymph
node tissue revealed multiple complex clonal abnormalities
(Table I). The bone marrow sample showed normal male karyo-
type without lymphoma involvement.
The patient received chemotherapy as per Pediatric Oncology
Group 9425 protocol consisting of doxorubicin, bleomycin, vin-
cristine, etoposide, prednisolone, and cyclophosphamide (ABVE-
PC). He did not achieve complete remission after completing a
total of seven courses of ABVE-PC chemotherapy. A follow-up
PET scan performed after completion of chemotherapy revealed a
variable response to treatment with increase in size and intensity
of right and left upper lobe lung lesions. In view of primary
refractory and progressive disease, he received two cycles of high
dose ifosfamide, carboplatin, and etoposide chemotherapy fol-
lowed by ASCT.
A year following his initial diagnosis, he received carmustine,
etoposide, cytarabine, and melphalan, followed by ASCT with
3.20  106/kg CD 34 þ cells. A follow-up PET scan revealed
decreased FDG uptake in most of the tumor, but three foci of
abnormal FDG uptake were still seen in the prevascular space in
the mediastinum. He received 30 Gy of radiation to the involved
chest fields, after which complete remission of HL was achieved
and he had remained asymptomatic for 18 months.
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Two years after ASCT, he presented with a 10 cm 
8 cm  6 cm hard immobile subcutaneous lesion involving the
left scapula. The lesion was in the field exposed to prior radio-
therapy for HL. On evaluation increased FDG uptake was noted
on PET scan. Complete local excision of the lesion was done,
which showed inflammatory type of malignant fibrous histiocy-
toma with anaplasia. In view of malignant nature of the tumor a
wide local re-excision was performed, it showed granulation tis-
sue with foreign body reaction without any evidence of tumor.
Metastatic work-up was negative. Surgical resection was followed
by 60 Gy of electron beam therapy to the tumor bed. One year
after the radiotherapy, the patient continues to be without evi-
dence of HL or MFH.
Cytogenetic analysis on the tissue samples from the two sur-
gical resections revealed two and three different unrelated abnor-
mal clonal tumor cells, respectively (Table I). In view of marked
chromosomal aberrations seen in HL, MFH, and granulation tis-
sue, and short interval between initial therapy for HL and devel-
opment of MFH, spectral karyotyping (SKY) analysis for
genomic instability was performed using peripheral blood
lymphocytes [9]. According to standard medical genetics practice,
clonal chromosomal aberration (CCA) is reported to be present
when the same chromosomal aberration is detected at least twice
within 20–40 mitotic figures [10]. Based on this practice standard,
CCAs refer to common aberrations with over 4–15% occurrence
among the examined cell population. In agreement with this
standard, non-clonal chromosome aberration (NCCA) is defined
as aberrations with a frequency of less than 4%. In our patient,
based on 48 SKY analyzed mitotic figures, there was no CCA
detected. However, there was a high level of NCCAs observed
pointing at genome instability (Fig. 1) [11–13]. In healthy indi-
viduals, cultured lymphocytes show a very low percentage of
NCCA, ranging from 0 to 2% [14]. However, in our patient,
the frequency of NCCA was 35% among examined mitotic
figures, of these 15% were structural NCCA and 20% were the
numerical NCCAs (mainly aneuploidy). Interestingly, there was
also high frequency of defective mitotic figures (DMF), which
are a type of structural NCCA that is also associated with genome
instability [11–13]. Based on the examination of 189 Giemsa-
stained mitotic figures, the DMF frequency was very high at
15% [12,13].
DISCUSSION
Malignant fibrous histiocytoma, a type of STS has been
reported following radiation therapy in HL [5–8]. Though the
absolute risk of developing MFH is not known, relative risk
(RR) of developing STS is the highest among all SM (RR-135)
[3,4]. Multiple unrelated clonal abnormalities are not uncommon
TABLE I. Karyotypes in Various Tissues
Site Tissue diagnosis Karyotype findings
Lymph node- at diagnosis Hodgkin lymphoma 46,XY[cp18]
48,XY,þX,add(4)(q21),þ5,þ9,del(9)(p13), add(12)(q24.3),
13, t(14;15) (q10;q10),þ17[cp2]
Bone marrow- at diagnosis Normal 46, XY [20]
Soft tissue mass MFH 46,XY,inv(6)(p21p25) [13]
46,XY,t(3;13)(q12;q34) [2]
46,XY [nonclonal abnormalities 5]
Soft tissue surrounding tumor Granulation tissue and foreign 45,X,Y,t(1;2)(p32;q37),inv(6)(p21q21),der





Fig. 1. Representative examples of NCCA. Upper image shows
t(15;11;18) and three copies of chromosome 17 and 19. Lower
image shows the translocation between chromosome 1 and 2.
[Color figure can be viewed in the online issue, which is available
at wileyonlinelibrary. com.]
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in STS, it has been documented to occur in three out of the ten
cases of post radiation sarcomas reported by Mertens et al. [15].
Most cases of MFH have been reported to occur in adults (18–59
years) who have received more than 40 Gy (40–53 Gy) of radio-
therapy and most of them developed MFH after a latent period of
more than 10 years [5–8]. The shortest latency period reported in
a series of post-radiation sarcoma cases in HL was four years [5].
In our patient, despite smaller radiation dose (30 Gy), MFH
developed within 18 months of RT and 34 months of initial
therapy, which is very unusual. High dose chemotherapy and
ASCT are known to increase the risk of SM [5,8]. Presence of
multiple unrelated clonal karyotype abnormalities in both MFH
and granulation tissue and very short latency prompted us to
investigate for underlying predisposition to malignancy in our
case. Although there was no tumor tissue identified by micro-
scopy, there is a possibility of contaminating malignant cells
among the reactive tissue cells.
Multiple non-specific numerical and structural aberrations of
chromosomes have been well documented in HL [16]. Heng et al.
have recently proposed that genomic instability leading to NCCA
aberrations might be the main factor in malignant transformation
and progression in a majority of cancers [12,17]. NCCA is a
newly identified marker of overall genome instability [11–13].
The frequencies of NCCA have been directly linked to tumor-
igenicity [18]. In normal individuals, the frequency of NCCA in
their cultured blood lymphocytes is between 0 and 2% [14]. The
elevated frequency of NCCA (35%) detected in our case suggests
high level genome instability. However, it is not clear how much
of this high-level of instability is caused by recent exposure to
chemotherapy or from the individual’s inherent chromosomal
instability. Nevertheless, further radiation exposure to the local
tissue with already known karyotype abnormalities can increase
the risk of other SM in our case.
Multiple loci of chromosomal instability (16p11.2, 15q13, and
7q) and increased incidence of PTEN mutations have been ident-
ified in a small percentage of children with autism [19,20]. To
date, there have been no studies to see whether the genomic
instability noted in these patients are associated with increased
NCCA, which if present, might predispose them to the develop-
ment of malignancy. In our case, though the SKY results were
very abnormal, the initial karyotype done at the time of diagnosis
was normal by classical cytogenetics. Further investigation
specifically looking for known loci of chromosomal instability
in autism was not performed. In future more studies are needed
to better understand the possible association.
In conclusion, the development of MFH as an SM much earlier
than normally seen in survivors of HL is very unusual. The
presence of multiple clonal cytogenetic abnormalities in tumor
and reactive tissues, and further demonstration of high-level
NCCA in peripheral blood lymphocytes suggest genome instabil-
ity in our patient.
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